Sirio launches postbiotic gummy using Cargill’s EpiCor

Gummy supplements. Image courtesy of Sirio Pharma.

Sirio Pharma Co. Ltd. has announced the launch of a postbiotic gummy that features EpiCor, a postbiotic yeast fermentate ingredient from Cargill that is backed by eight human and eight pre-clinical studies. The gummy, called BloomDays, targets immune health via the gut by delivering 500 mg of EpiCor per 2-gummy serving.

"We are truly excited to collaborate with Cargill – a global leader committed to nourishing the world in a safe, responsible, and sustainable way to introduce an exceptional product that combines our strengths in health and wellness innovation," said Sara Lesina, general manager Europe and Americas for Sirio, in a press release. "BloomDays represents a milestone in our commitment to collaborating with reputable ingredients suppliers to launch innovative and unique solutions for our customers, helping them win in the market. BloomDays not only tastes great and provides meaningful health benefits but also offers a unique value proposition.”

"We are excited to collaborate with Sirio as they make the health benefits of EpiCor available to more people through the introduction of their new, postbiotic gummy,” added Adam Hertell, global commercial director of dietary supplements for EpiCor. “With excellent stability properties, EpiCor offers the versatility and simplicity that pairs well with gummy manufacturing, making for a winning combination.”

The postbiotic gummy will make its official debut at Natural Product Expo West 2024, at the Anaheim Convention Center, taking place between March 14 and 16. Attendees will be able to taste BloomDays at booth #3905. Eventually, the product will be launched in Europe in the second half of 2024 at CHPI Milan.